Increased fetal nuchal translucency at 11-14 weeks

被引:124
作者
Nicolaides, KH [1 ]
Heath, V [1 ]
Cicero, S [1 ]
机构
[1] Kings Coll Hosp London, Harris Birthright Ctr Fetal Med, London SE5 8RX, England
关键词
nuchal translucency (NT); chromosomal defects; fetal abnormalities; ultrasonography; screening; free-beta human chorionic gonadotrophin (beta-hCG) pregnancy-associated plasma protein-A (PAPP-A);
D O I
10.1002/pd.308
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Nuchal translucency (NT) is the sonographic appearance of a subcutaneous collection of fluid behind the fetal neck. The measurement of fetal NT thickness at the 11-14-week scan has been combined with maternal age to provide an effective method of screening for trisomy 21; for an invasive testing rate of 5%, about 75% of trisomic pregnancies can be identified. When maternal serum free-beta human chorionic gonadotrophin (beta-hCG) and pregnancy-associated plasma protein-A (PAPP-A) at 11-14 weeks are also taken into account, the detection rate of chromosomal defects is about 90%. Increased NT can also identify a high proportion of other chromosomal abnormalities and is associated with major defects of the heart and great arteries, and a wide range of skeletal dysplasias and genetic syndromes. In monochorionic twins, discordancy for increased NT is an early marker of twin-to-twin transfusion syndrome (TTTS). As with the introduction of any new technology into routine clinical practice, it is essential that those undertaking the 11-14-week scan are adequately trained and their results are subjected to rigorous audit. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:308 / 315
页数:8
相关论文
共 62 条
[11]   EARLY DIAGNOSIS OF FETAL CONGENITAL HEART-DISEASE BY TRANSVAGINAL ECHOCARDIOGRAPHY [J].
GEMBRUCH, U ;
KNOPFLE, G ;
BALD, R ;
HANSMANN, M .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1993, 3 (05) :310-317
[12]  
GEMBRUCH U, 1990, OBSTET GYNECOL, V75, P496
[13]   NEW ESTIMATES OF DOWN-SYNDROME RISKS AT CHORIONIC VILLUS SAMPLING, AMNIOCENTESIS, AND LIVEBIRTH IN WOMEN OF ADVANCED MATERNAL AGE FROM A UNIQUELY DEFINED POPULATION [J].
HALLIDAY, JL ;
WATSON, LF ;
LUMLEY, J ;
DANKS, DM ;
SHEFFIELD, LJ .
PRENATAL DIAGNOSIS, 1995, 15 (05) :455-465
[14]   THE IMPRECISION IN RATES OF DOWN-SYNDROME BY 1-YEAR MATERNAL AGE INTERVALS - A CRITICAL ANALYSIS OF RATES USED IN BIOCHEMICAL SCREENING [J].
HECHT, CA ;
HOOK, EB .
PRENATAL DIAGNOSIS, 1994, 14 (08) :729-738
[15]   Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study [J].
Hyett, J ;
Perdu, M ;
Sharland, G ;
Snijders, R ;
Nicolaides, KH .
BRITISH MEDICAL JOURNAL, 1999, 318 (7176) :81-85
[16]  
Hyett J, 1997, AM J MED GENET, V69, P207, DOI 10.1002/(SICI)1096-8628(19970317)69:2<207::AID-AJMG18>3.0.CO
[17]  
2-P
[18]   Lethal congenital arthrogryposis presents with increased nuchal translucency at 10-14 weeks of gestation [J].
Hyett, J ;
Noble, P ;
Sebire, NJ ;
Snijders, R ;
Nicolaides, KH .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1997, 9 (05) :310-313
[19]   Cardiac gene expression of atrial natriuretic peptide and brain natriuretic peptide in trisomic fetuses [J].
Hyett, JA ;
Bizot, ML ;
VonKaisenberg, CS ;
McKie, AT ;
Farzaneh, F ;
Nicolaides, KH .
OBSTETRICS AND GYNECOLOGY, 1996, 87 (04) :506-510
[20]   Increased nuchal translucency at 10-14 weeks of gestation as a marker for major cardiac defects [J].
Hyett, JA ;
Perdu, M ;
Sharland, GK ;
Snijders, RSM ;
Nicolaides, KH .
ULTRASOUND IN OBSTETRICS & GYNECOLOGY, 1997, 10 (04) :242-246